Women with neurofibromatosis type 1 (NF1) have up to a 5-fold increased risk for breast cancer before age 50 and a 3.5-fold increased risk of breast cancer overall. The purpose of our study was to assess breast cancer screening utilization and outcomes in this population.
Patients and Methods
This IRB approved HIPAA compliant study retrospectively assessed consecutive NF1 patients (January 2012-December 2021) with recorded clinical visits and/or breast imaging. Patient demographics, risk factors, and screening mammogram and breast magnetic resonance imaging (MRI) outcomes were recorded. Descriptive statistics were obtained and standard breast screening measures were calculated.
One hundred and eleven women (median age 43, range 30-82) were eligible for screening based on current NCCN guidelines. A total of 86% (95/111) of all patients and 80% (24/30) of patients under age 40 had at least 1 mammogram. In contrast, 28% (31/111) of all patients and 33% (25/76) of patients ages 30 to 50 had at least 1 screening MRI. Of 368 screening mammograms performed, 38 of 368 (10%) resulted in the recall, and 22 of 368 (6%) resulted in a biopsy. Of 48 screening MRIs performed, 19 of 48 (40%) short-term follow-ups and 12 of 48 (25%) biopsies were recommended. All 6 screen-detected cancers in our cohort were detected initially on screening mammograms.
Results confirm the utility and performance of screening mammography in the NF1 population. The low utilization of MRI in our cohort limits the evaluation of outcomes via this modality and suggests there may be an education or interest gap among referrers and patients regarding supplemental screening recommendations.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Clinical Breast Cancer
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- The clinical and diagnostic implications of mosaicism in the neurofibromatoses.Neurology. 2001; 56: 1433-1443https://doi.org/10.1212/wnl.56.11.1433
- Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service.Am J Med Genet A. 2010; 152A: 327-332https://doi.org/10.1002/ajmg.a.33139
- Use of the national institutes of health criteria for diagnosis of neurofibromatosis 1 in children.Pediatrics. 2000; 105: 608-614https://doi.org/10.1542/peds.105.3.608
- von Recklinghausen neurofibromatosis. II. Incidence of optic gliomata.Ophthalmology. 1984; 91: 929-935https://doi.org/10.1016/s0161-6420(84)34217-8
- Comparison of cancer prevalence in patients with neurofibromatosis type 1 at an academic cancer center vs in the general population from 1985 to 2020.JAMA Netw Open. 2021; 4e210945https://doi.org/10.1001/jamanetworkopen.2021.0945
- Increased breast cancer risk in women with neurofibromatosis type 1: a meta-analysis and systematic review of the literature.Hered Cancer Clin Pract. 2019; 17: 12https://doi.org/10.1186/s13053-019-0110-z
- Mortality in neurofibromatosis 1: an analysis using U.S. death certificates.Am J Hum Genet. 2001; 68: 1110-1118https://doi.org/10.1086/320121
- Breast cancer in women with neurofibromatosis type 1 (NF1): a comprehensive case series with molecular insights into its aggressive phenotype.Breast Cancer Res Treat. 2018; 171: 719-735https://doi.org/10.1007/s10549-018-4851-6
- Breast cancer in neurofibromatosis type 1: overrepresentation of unfavourable prognostic factors.Br J Cancer. 2017; 116: 211-217https://doi.org/10.1038/bjc.2016.403
- Increased risk of breast cancer in women with NF1.Am J Med Genet A. 2012; 158A: 3056-3060https://doi.org/10.1002/ajmg.a.35550
- Women with neurofibromatosis 1 are at a moderately increased risk of developing breast cancer and should be considered for early screening.J Med Genet. 2007; 44: 481-484https://doi.org/10.1136/jmg.2007.049346
- Breast cancer and other neoplasms in women with neurofibromatosis type 1: a retrospective review of cases in the Detroit metropolitan area.Am J Med Genet A. 2012; 158A: 3061-3064https://doi.org/10.1002/ajmg.a.35560
- A prospective study of neurofibromatosis type 1 cancer incidence in the UK.Br J Cancer. 2006; 95: 233-238https://doi.org/10.1038/sj.bjc.6603227
- Genetic/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2021, NCCN clinical practice guidelines in oncology.J Natl Compr Canc Netw. 2021; 19: 77-102https://doi.org/10.6004/jnccn.2021.0001
- ACR BI-RADS® Atlas, Breast Imaging Reporting and Data System.American College of Radiology, Reston, VA2013
- Breast cancer screening in women at higher-than-average risk: recommendations from the ACR.J Am Coll Radiol. 2018; 15: 408-414https://doi.org/10.1016/j.jacr.2017.11.034
- National performance benchmarks for modern screening digital mammography: update from the breast cancer surveillance consortium.Radiology. 2017; 283: 49-58https://doi.org/10.1148/radiol.2016161174
- Adherence to the breast cancer surveillance program for women at risk for familial breast and ovarian cancer versus overscreening: a monocenter study in Germany.Breast Cancer Res Treat. 2016; 156: 289-299https://doi.org/10.1007/s10549-016-3748-5
- NF1 patients receiving breast cancer screening: insights from the Ontario high risk breast screening program.Cancers (Basel). 2019; 11https://doi.org/10.3390/cancers11050707
- Breast cancer screening adherence at multiple timepoints over eight years among women in a familial cohort.J Clin Oncol. 2019; 37: 1557https://doi.org/10.1200/JCO.2019.37.15_suppl.1557
- Trends in screening breast magnetic resonance imaging use among US women, 2006 to 2016.Cancer. 2020; 126: 5293-5302https://doi.org/10.1002/cncr.33140
- Recent trends in screening breast MRI.J Breast Imaging. 2022; 4: 39-47https://doi.org/10.1093/jbi/wbab088
- Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging.JAMA. 2006; 295: 2374-2384https://doi.org/10.1001/jama.295.20.2374
- Cost-effectiveness of screening with contrast enhanced magnetic resonance imaging vs X-ray mammography of women at a high familial risk of breast cancer.Br J Cancer. 2006; 95: 801-810https://doi.org/10.1038/sj.bjc.6603356
- Magnetic resonance imaging in screening of breast cancer.Radiol Clin North Am. 2021; 59: 85-98https://doi.org/10.1016/j.rcl.2020.09.004
- The psychological impact and experience of breast cancer screening in young women with an increased risk of breast cancer due to neurofibromatosis type 1.Fam Cancer. 2022; 21: 241-253https://doi.org/10.1007/s10689-021-00259-9
- Emotional functioning of patients with neurofibromatosis tumor suppressor syndrome.Genet Med. 2012; 14: 977-982https://doi.org/10.1038/gim.2012.85
- Breast cancer and neurofibromatosis type 1: a diagnostic challenge in patients with a high number of neurofibromas.BMC Cancer. 2015; 15: 183https://doi.org/10.1186/s12885-015-1215-z
- A hidden breast lump covered by nipple appendices in a patient with von Recklinghausen disease: a case report and review of the literature.Clin Breast Cancer. 2012; 12: 71-75https://doi.org/10.1016/j.clbc.2011.07.005
- Effectiveness of screening with annual magnetic resonance imaging and mammography: results of the initial screen from the Ontario high risk breast screening program.J Clin Oncol. 2014; 32: 2224-2230https://doi.org/10.1200/JCO.2013.52.8331
- Increased risk of breast cancer in neurofibromatosis type 1: current insights.Breast Cancer (Dove Med Press). 2017; 9: 531-536https://doi.org/10.2147/BCTT.S111397
Published online: February 12, 2023
Accepted: February 8, 2023
Received in revised form: January 21, 2023
Received: November 17, 2022
Publication stageIn Press Journal Pre-Proof
© 2023 Elsevier Inc. All rights reserved.